Monika W. Perez

Monika W. Perez

Auto-generated profile, based on publicly available information

Monika W. Perez

Department of Genome Sciences, University of Washington

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2022 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
KEKenneth Eagle
Kenneth Eagle
THTaku Harada
Taku Harada
JKJérémie Kalfon
Jérémie Kalfon
MPMonika W. Perez
Monika W. Perez
YHYaser Heshmati
Yaser Heshmati
MPMaxim Pimkin
Maxim Pimkin
Relapse of acute myeloid leukemia (AML) after allogeneic bone marrow transplantation has been linked to immune evasion due to reduced expression of major histocompatibility complex class II (MHCII) genes through unknown mechanisms. In this work, we developed CORENODE, a computational algorithm for genome-wide transcription network decomposition that identified a transcription factor (TF) tetrad consisting of IRF8, MYB, MEF2C, and MEIS1, regulating MHCII expression in AML cells. We show that reduced MHCII expression at relapse is transcriptionally driven by combinatorial changes in the expression of these TFs, where MYB and IRF8 play major opposing roles, acting independently of the IFNγ/CIITA pathway. Beyond the MHCII genes, MYB and IRF8 antagonistically regulate a broad genetic program responsible for cytokine signaling and T-cell stimulation that displays reduced expression at relapse. A small number of cells with altered TF abundance and silenced MHCII expression are present at the time of initial leukemia diagnosis, likely contributing to eventual relapse. Significance: Our findings point to an adaptive transcriptional mechanism of AML evolution after allogeneic transplantation whereby combinatorial fluctuations of TF expression under immune pressure result in the selection of cells with a silenced T-cell stimulation program. This article is highlighted in the In This Issue feature, p. 369

17 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NBNathaniel J Buteyn
Nathaniel J Buteyn
SLSamantha J LaMantia
Samantha J LaMantia
CBConnor G Burke
Connor G Burke
VSVincent J Sartori
Vincent J Sartori
EDEve Deering-Gardner
Eve Deering-Gardner
TTTimothy J Triche
Timothy J Triche
The past 25 years of clinical trials have produced few improvements in pediatric AML (pAML) outcomes. This is acutely evident in patients with t(16;21)(p11;q22), yielding FUS::ERG . Patients with FUS::ERG -positive AML relapse quickly and do not respond to transplantation. Major histocompatibility complex (MHC) class I & II receptors and costimulatory molecules are absent at diagnosis in FUS::ERG- positive AML, mirroring the phenotype and outcomes of post-transplant relapse. We show that this is driven by overexpression of EZH2, in vitro and in multiple clinical cohorts. While FUS::ERG AML is the most extreme example, this phenotype is shared by lethal CBFA2T3::GLIS2- driven AML, and patients with RUNX1::RUNX1T1 have significantly worse outcomes when EZH2 overexpression co-occurs. The FDA-approved EZH2 inhibitor tazemetostat reverses this phenotype, re-establishes MHC presentation, and elicits immune effector cell-mediated elimination. EZH2 inhibitors may provide the first targeted therapeutic frontline option for AML patients with FUS::ERG , with the potential for broader frontline immunostimulatory benefits. STATEMENT OF SIGNIFICANCE: Here we show an immune-evasive phenotype, present at diagnosis and characterized by elevated EZH2 levels and loss of MHC class I and II, defines a high-risk subtype of acute leukemia. Treatment with the EZH2 inhibitor tazemetostat and IFN-γ reverses this phenotype and results in immune cell engagement and blast elimination.

4 April 2023
Verified
Other
Open access
KEKenneth Eagle
Kenneth Eagle
THTaku Harada
Taku Harada
JKJérémie Kalfon
Jérémie Kalfon
MPMonika W. Perez
Monika W. Perez
YHYaser Heshmati
Yaser Heshmati
MPMaxim Pimkin
Maxim Pimkin
Supplementary Figure from Transcriptional Plasticity Drives Leukemia Immune Escape

4 April 2023
Verified
Other
Open access
KEKenneth Eagle
Kenneth Eagle
THTaku Harada
Taku Harada
JKJérémie Kalfon
Jérémie Kalfon
MPMonika W. Perez
Monika W. Perez
YHYaser Heshmati
Yaser Heshmati
MPMaxim Pimkin
Maxim Pimkin

4 April 2023
Verified
Other
Open access
KEKenneth Eagle
Kenneth Eagle
THTaku Harada
Taku Harada
JKJérémie Kalfon
Jérémie Kalfon
MPMonika W. Perez
Monika W. Perez
YHYaser Heshmati
Yaser Heshmati
MPMaxim Pimkin
Maxim Pimkin
Supplementary Data from Transcriptional Plasticity Drives Leukemia Immune Escape

4 April 2023
Verified
Other
Open access
KEKenneth Eagle
Kenneth Eagle
THTaku Harada
Taku Harada
JKJérémie Kalfon
Jérémie Kalfon
MPMonika W. Perez
Monika W. Perez
YHYaser Heshmati
Yaser Heshmati
MPMaxim Pimkin
Maxim Pimkin